Parkside Financial Bank & Trust Sells 122 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Parkside Financial Bank & Trust decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 885 shares of the medical research company’s stock after selling 122 shares during the period. Parkside Financial Bank & Trust’s holdings in Thermo Fisher Scientific were worth $470,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Raleigh Capital Management Inc. lifted its stake in Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 107.0% during the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after purchasing an additional 46 shares in the last quarter. Financial Connections Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $53,000. Operose Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 250.0% during the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after purchasing an additional 75 shares in the last quarter. Finally, Valley National Advisers Inc. raised its stake in shares of Thermo Fisher Scientific by 40.5% during the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock worth $56,000 after purchasing an additional 32 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. The Goldman Sachs Group upped their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Evercore ISI boosted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Raymond James boosted their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded up $26.15 during trading on Tuesday, reaching $574.53. 1,687,234 shares of the company traded hands, compared to its average volume of 1,550,355. The company’s 50 day moving average is $571.30 and its two-hundred day moving average is $528.18. The firm has a market capitalization of $219.30 billion, a PE ratio of 35.49, a PEG ratio of 2.30 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the prior year, the company earned $5.40 EPS. Thermo Fisher Scientific’s revenue for the quarter was down 4.9% on a year-over-year basis. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.